文献速递脑血管病

C反应蛋白、白细胞介素-6与不同卒中亚型的血管性复发:个体参与者数据Meta分析

C-Reactive Protein, Interleukin-6, and Vascular Recurrence According to Stroke Subtype: An Individual Participant Data Meta-Analysis.
PubMed 文献 · Neurology · 2023-12-19

该个体参与者数据Meta分析纳入10项研究共8420例缺血性卒中或短暂性脑缺血发作患者,分析高敏C反应蛋白和白细胞介素-6与血管性复发的关联。校正血管危险因素和他汀/抗血栓治疗后,白细胞介素-6与大动脉粥样硬化型、不明原因型和小血管闭塞型卒中的复发性主要不良心血管事件相关,高敏C反应蛋白仅与不明原因型卒中的复发性主要不良心血管事件相关。

要点

  • 白细胞介素-6与大动脉粥样硬化型、不明原因型和小血管闭塞型卒中的复发性主要不良心血管事件相关(Q4 vs Q1)。
  • 高敏C反应蛋白仅与不明原因型卒中的复发性主要不良心血管事件相关(Q4 vs Q1 RR 1.45)。
  • 心源性栓塞型或其他明确病因型卒中未观察到炎症标志物与复发性主要不良心血管事件的关联。

核心结论

  • 数据为未来抗炎治疗随机对照试验中根据炎症标志物特征选择大动脉粥样硬化型、小血管闭塞型和不明原因型卒中患者提供了新证据。

研究设计与样本

  • 通过系统综述识别个体参与者数据,分析高敏C反应蛋白、白细胞介素-6与缺血性卒中或短暂性脑缺血发作后血管性复发的关联,并按卒中机制分层。
  • 个体参与者数据来自10项研究共8420例患者;随后与研究层面Meta分析中另外2项可比研究(20136例患者)的结果进行合并。

主要发现

  • 校正血管危险因素和他汀/抗血栓治疗后,白细胞介素-6与大动脉粥样硬化型卒中的复发性主要不良心血管事件相关(Q4 vs Q1 RR 2.30,95% CI 1.21-4.36,p=0.01)。
  • 白细胞介素-6与不明原因型卒中的复发性主要不良心血管事件相关(Q4 vs Q1 RR 1.78,95% CI 1.19-2.66,p=0.005)。
  • 白细胞介素-6与小血管闭塞型卒中的复发性主要不良心血管事件相关(Q4 vs Q1 RR 1.71,95% CI 0.99-2.96,p=0.053)。
  • 按每loge单位增加分析主要不良心血管事件时,大动脉粥样硬化型RR 1.26(95% CI 1.06-1.50,p=0.009),小血管闭塞型RR 1.22(95% CI 1.01-1.47,p=0.04),不明原因型RR 1.18(95% CI 1.04-1.34,p=0.01)。
  • 高敏C反应蛋白仅与不明原因型卒中的复发性主要不良心血管事件相关(Q4 vs Q1 RR 1.45,95% CI 1.04-2.03,p=0.03)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Anti-inflammatory therapies reduce major adverse cardiovascular events (MACE) in coronary artery disease but remain unproven after stroke. Establishing the subtype-specific association between inflammatory markers and recurrence risk is essential for optimal selection of patients in randomized trials (RCTs) of anti-inflammatory therapies for secondary stroke prevention. METHODS: Using individual participant data (IPD) identified from a systematic review, we analyzed the association between high-sensitivity C-reactive protein, interleukin-6 (IL-6), and vascular recurrence after ischemic stroke or transient ischemic attack. The prespecified coprimary end points were (1) any recurrent MACE (first major coronary event, recurrent stroke, or vascular death) and (2) any recurrent stroke (ischemic, hemorrhagic, or unspecified) after sample measurement. Analyses were performed stratified by stroke mechanism, per quarter and per biomarker unit increase after loge transformation. We then did study-level meta-analysis with comparable published studies not providing IPD. Preferred Reporting Items for Systematic Review and Meta-Analyses IPD guidelines were followed. RESULTS: IPD was obtained from 10 studies (8,420 patients). After adjustment for vascular risk factors and statins/antithrombotic therapy, IL-6 was associated with recurrent MACE in stroke caused by large artery atherosclerosis (LAA) (risk ratio [RR] 2.30, 95% CI 1.21-4.36, p = 0.01), stroke of undetermined cause (UND) (RR 1.78, 1.19-2.66, p = 0.005), and small vessel occlusion (SVO) (RR 1.71, 0.99-2.96, p = 0.053) (quarter 4 [Q4] vs quarter 1 [Q1]). No association was observed for stroke due to cardioembolism or other determined cause. Similar results were seen for recurrent stroke and when analyzed per loge unit increase for MACE (LAA, RR 1.26 [1.06-1.50], p = 0.009; SVO, RR 1.22 [1.01-1.47], p = 0.04; UND, RR 1.18 [1.04-1.34], p = 0.01). High-sensitivity CRP was associated with recurrent MACE in UND stroke only (Q4 vs Q1 RR 1.45 [1.04-2.03], p = 0.03). Findings were consistent on study-level meta-analysis of the IPD results with 2 other comparable studies (20,136 patients). DISCUSSION: Our data provide new evidence for the selection of patients in future RCTs of anti-inflammatory therapy in stroke due to large artery atherosclerosis, small vessel occlusion, and undetermined etiology according to inflammatory marker profile.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. McCabe JJ, Walsh C, Gorey S, et al. C-Reactive Protein, Interleukin-6, and Vascular Recurrence According to Stroke Subtype: An Individual Participant Data Meta-Analysis. Neurology. 2023. PMID: 38165328. doi:10.1212/WNL.0000000000208016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。